Trump's NIH cuts are gutting university labs that fuel Big Pharma's drug pipeline and pushing U.S. biotech jobs, research, ...

That challenge, of finding or building good, useable data sets, is also one of the biggest differentiators in an increasingly ...

AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a ...

Biogen has emerged as a potential front-runner at the Cannes Lions International Festival of Creativity, snagging four spots ...

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

The recent experience of Chinese biotech companies in developing their own drug candidates and inking deals with larger ...

Amid a spate of high-profile investments in U.S. pharmaceutical production, two contract manufacturers are getting in on the ...

Navigating a complex drug development landscape, sponsors must rethink their approach to risk in study design and execution.

The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...